Shares of Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.25.
A number of equities analysts have issued reports on the company. Barclays increased their price target on Solid Biosciences from $8.00 to $21.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. William Blair reiterated an “outperform” rating on shares of Solid Biosciences in a research report on Thursday, March 28th. Citigroup assumed coverage on Solid Biosciences in a research report on Friday, March 15th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Thursday, March 14th. Finally, Piper Sandler upgraded Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $8.00 to $20.00 in a research report on Thursday, March 14th.
Check Out Our Latest Research Report on SLDB
Hedge Funds Weigh In On Solid Biosciences
Solid Biosciences Stock Up 5.2 %
Solid Biosciences stock opened at $8.98 on Monday. The firm has a market cap of $339.71 million, a price-to-earnings ratio of -1.86 and a beta of 1.93. Solid Biosciences has a 52 week low of $1.81 and a 52 week high of $15.05. The business’s 50-day moving average price is $11.08 and its 200 day moving average price is $6.98. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 0.01.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.01. As a group, sell-side analysts anticipate that Solid Biosciences will post -2.64 earnings per share for the current year.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Read More
- Five stocks we like better than Solid Biosciences
- Investing in the High PE Growth Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Trading Halts Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.